FDA review of oral MS drug FTY720 extended
FDA review of oral MS drug FTY720 extended
Novartis International AG / Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy.
* US Food and Drug Administration (FDA) extends priority review period by three months to September 2010, in line with previously announced expectations............. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309 ]
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1830 Views
-
Last post by frodo
-
- 0 Replies
- 1187 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 1175 Views
-
Last post by NHE
-
- 1 Replies
- 1637 Views
-
Last post by frodo
-
- 0 Replies
- 1655 Views
-
Last post by frodo
-
- 0 Replies
- 2221 Views
-
Last post by NHE
-
- 0 Replies
- 1033 Views
-
Last post by frodo
-
- 0 Replies
- 1739 Views
-
Last post by frodo